Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Notes Payables: 2011-2021

Historic Notes Payables for Adma Biologics (ADMA) over the last 1 years, with Mar 2021 value amounting to $100.0 million.

  • Adma Biologics' Notes Payables was N/A to $100.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $100.0 million, marking a year-over-year change of. This contributed to the annual value of $100.0 million for FY2020, which is N/A change from last year.
  • As of Q1 2021, Adma Biologics' Notes Payables stood at $100.0 million, which was down 0.00% from $100.0 million recorded in Q4 2020.
  • In the past 5 years, Adma Biologics' Notes Payables ranged from a high of $100.0 million in Q4 2020 and a low of $6.7 million during Q1 2017.
  • In the last 2 years, Adma Biologics' Notes Payables had a median value of $100.0 million in 2021 and averaged $95.0 million.
  • Data for Adma Biologics' Notes Payables shows a peak YoY soared of 50.00% (in 2017) over the last 5 years.
  • Over the past 4 years, Adma Biologics' Notes Payables (Quarterly) stood at $30.0 million in 2017, then remained steady at $30.0 million in 2018, then reached $100.0 million in 2020, then reached $100.0 million in 2021.
  • Its last three reported values are $100.0 million in Q1 2021, $100.0 million for Q4 2020, and $85.0 million during Q3 2020.